Company Overview of Cell>Point L.L.C.
Cell>Point L.L.C., a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy. Its products include 99mTc-EC-G (oncology), a metabolic imaging agent used to diagnose hyper metabolic activity in cancer cells; 99mTc-EC-G (cardiology), a functional imaging agent for use in cardiac imaging; 68Ga-EC-G that is used for PET imaging applications; and 99mTc-EC-Metronidazole (Stroke), a functional imaging agent for differentiating between hemorrhagic and ischemic strokes. Its products also comprise 187Re-EC-G, a cold metallic therapeutic agent used for the treatment of breast, non-smal...
7120 East Orchard Road
Centennial, CO 80111
Founded in 2001
Key Executives for Cell>Point L.L.C.
Compensation as of Fiscal Year 2013.
Cell>Point L.L.C. Key Developments
Cell>Point L.L.C. Announces Encouraging Results from (99m) Tc--EC--G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease
Apr 9 13
Cell>Point L.L.C. announced results from conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled EthylenediCysteine-Glucosamine (99mTc-EC-G), Cell>Point's proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of ischemia in patients with Coronary Artery Disease (CAD). The results from the Phase 1 and 2a studies show that 99mTc-EC-G has the potential to accurately diagnose myocardial ischemia (that is, decrease in blood flow and oxygen to heart muscle) in as little as 30 minutes post injection in patients studied at rest only. The multicenter Phase 2b trial will evaluate the diagnostic accuracy (sensitivity and specificity) of a 99mTc-EC-G study performed at rest only compared to a two-day 99mTc-Cardiolite rest/stress study to determine the presence, anatomical location, and severity of ischemia in patients with CAD. Diagnostic catheterization will be used as the standard of truth. Camargo Pharmaceutical Services of Cincinnati will perform the role of general manager over the clinical research and regulatory function for the study. Premier Research of Research Triangle Park, North Carolina, will continue their role as the clinical research organization for the study.
Cell>Point L.L.C. and Hyun Imc Co. Ltd Expand License in South Korea to Include Hanmi Science Co., Ltd. for Cancer and Heart Disease Imaging
Mar 11 13
Cell>Point L.L.C. announced that it entered into a license agreement on December 17, 2012 with Hanmi Science Co., Ltd. The license agreement also includes Hyun Imc Co. Ltd. as a party (who Cell>Point previously entered into a license with in February 2012 and subsequently amended and restated the license agreement with HYUN IMC on December 4, 2012). The license agreement with Hanmi covers the kit manufacture, marketing and distribution of Cell>Point's cancer and cardiology imaging product based on its Ethylenedicysteine-Glucosamine (EC-G) technology platform. The initial product will be technetium-99m labeled EC-G ((99m) Tc-EC-G) for SPECT and SPECT/CT imaging. Downstream, the license agreement will cover gallium-68 labeled EC-G ((68) Ga-EC-G) for PET/CT imaging. In addition, Hanmi has been granted a Right of First Refusal regarding Cell>Point's cold metallic therapeutic products Platinum-EC-G and (187) Rhenium-EC-G, and two imaging products, (99m) Tc-EC-Annexin V to image tumor cell apoptosis, and (99m) Tc-EC-Metronidazole to image tumor cell hypoxia. Cell>Point receives upfront payments, milestone progress payments, and a royalty on commercial sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 25, 2014